Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003726 · ClinicalTrials.gov registry record · Phase 1
Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00003726 is a Phase 1 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT00003726, a Phase 1 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in treating patients with recurrent or advanced small cell lung cancer.
Interventions
- BIOLOGICAL lepirudin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 1998-11 |
| Est. Completion | 2001-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003726
The ClinicalTrials.gov registry entry for NCT00003726 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lepirudin is the first listed.
NCT00003726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003726 about?
NCT00003726 is a clinical study titled "Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer". RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in treating patients with recurrent or advanced small...
What is the current status of trial NCT00003726?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 1998-11. Estimated completion is 2001-07.
What interventions are being tested in trial NCT00003726?
The interventions under investigation include: lepirudin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003726?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.